Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Gemigliptin/Dapagliflozin FDC vs Separate Components in Healthy Volunteers
NCT04544319Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Oct 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of gemigliptin + dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration and Maximum Plasma Concentration. Status: unknown.
02
Drugs
gemigliptin + dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04544319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544319.